The Rx Recap: June 16-20

Welcome to this week’s roundup of the most insightful and impactful articles from the sister publications of Dermatology Times, all under One MJH Life Sciences. Our network brings together expert perspectives, clinical advancements, and industry updates to keep clinicians informed and ahead of the curve. From cutting-edge treatments to practice management strategies, here’s a look at the top stories shaping the field of medicine.

Dual-Target CD19/CD20 CAR T-Cell Therapy Achieves 63.6% Complete Remission Rate in R/R B-NHL

Dual-target CAR-T therapy targeting CD19 and CD20 antigens has shown encouraging results in patients with relapsed/refractory B-cell non-Hodgkin lymphoma, according to findings presented at the European Hematology Association 2025 Congress, CGTLive reports. In a small study of 11 patients, researchers observed a complete remission rate of 63.6% and an overall response rate of 72.7% at 3 months, with no grade ≥3 cytokine release syndrome or any cases of ICANS reported. Designed to reduce antigen escape and improve tumor cell clearance, the dual-target strategy was well tolerated, with median overall and progression-free survival not yet reached at a median follow-up of over 20 months.

Medicare hospital insurance trust fund projected to be depleted in 2033

Medicare faces mounting financial challenges as its trust fund is now projected to be depleted by 2033—3 years earlier than previously estimated—according to the program’s 2025 trustees report, Medical Economics reports. The update warns that under current law, physician reimbursement is unlikely to keep pace with rising costs, potentially jeopardizing long-term access to care for Medicare beneficiaries. While 2024 spending reached $1.12 trillion and covered over 67 million Americans, future projections suggest Medicare could consume up to 8.8% of GDP by 2099 if physician payments are adjusted to economic indices.

Loss of 988 Hotline Services Tailored to LGBTQ+ Youth

The 988 National Suicide & Crisis Lifeline will discontinue its specialized support for LGBTQ+ youth on July 17, 2025, sparking widespread concern from mental health advocates, Psychiatric Times reports. The “Press 3” and “PRIDE” services, designed to address the unique challenges faced by LGBTQ+ youth, will be eliminated despite data showing this group is over 4 times more likely to attempt suicide than their peers. While SAMHSA maintains all 988 callers will continue to receive compassionate, culturally competent care, experts stress that removing tailored services may jeopardize trust and worsen outcomes for LGBTQ+ youth in crisis.

Mango-derived extract shows positive impact on cognition and mood in recent study

A new study has found that a proprietary Mangifera indica (mango) extract may enhance cognitive performance and stress management in e-sports gamers, Nutritional Outlook reports. In a randomized, double-blind, placebo-controlled trial, 60 healthy participants aged 18–45 took either 300 mg of the mango extract Stadice or a placebo daily for 7 days. Gamers who received the extract showed improvements in attention, working memory, response inhibition, and mood regulation, with no adverse effects reported.

Novel cardiology therapy for cats is launched

A new treatment for feline hypertrophic cardiomyopathy has entered the veterinary market with the launch of sirolimus delayed-release tablets (Felycin-CA1), dvm360 reports. Developed by TriviumVet and now under PRN Pharmacal, a Pegasus Laboratories brand, the drug received conditional FDA approval earlier this year and is set for release in late July 2025. Sirolimus, an mTOR inhibitor, targets the cellular mechanisms behind ventricular hypertrophy, offering a disease-modifying approach rather than just symptom relief. Lead investigator Joshua Stern, DVM, PhD, called the therapy a paradigm shift in feline cardiology, with once-weekly dosing options suitable for cats of all sizes.

Want to read more on specialty care, pharmacy, industry sciences, and more? Check out MJH Life Sciences full list of brands here.